Equities analysts expect Acceleron Pharma Inc (NASDAQ:XLRN) to post ($0.23) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Five analysts have provided estimates for Acceleron Pharma’s earnings, with estimates ranging from ($0.35) to ($0.11). Acceleron Pharma reported earnings per share of ($0.63) in the same quarter last year, which would suggest a positive year over year growth rate of 63.5%. The company is expected to report its next quarterly earnings report on Thursday, August 1st.
On average, analysts expect that Acceleron Pharma will report full year earnings of ($2.42) per share for the current financial year, with EPS estimates ranging from ($2.78) to ($1.98). For the next year, analysts anticipate that the firm will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.60) to ($1.17). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Acceleron Pharma.
Acceleron Pharma (NASDAQ:XLRN) last released its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.07). Acceleron Pharma had a negative net margin of 965.39% and a negative return on equity of 35.94%. The business had revenue of $2.78 million during the quarter, compared to analyst estimates of $3.67 million. During the same quarter last year, the company posted ($0.58) earnings per share. The company’s revenue was down 13.9% on a year-over-year basis.
In other Acceleron Pharma news, CFO Kevin F. Mclaughlin sold 648 shares of the stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $48.02, for a total transaction of $31,116.96. Following the sale, the chief financial officer now directly owns 42,279 shares in the company, valued at $2,030,237.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Kevin F. Mclaughlin sold 12,000 shares of the stock in a transaction dated Tuesday, April 9th. The stock was sold at an average price of $44.62, for a total transaction of $535,440.00. Following the sale, the chief financial officer now owns 30,379 shares in the company, valued at $1,355,510.98. The disclosure for this sale can be found here. Insiders have sold 23,730 shares of company stock worth $1,060,959 over the last quarter. Corporate insiders own 2.50% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the company. TimesSquare Capital Management LLC boosted its stake in shares of Acceleron Pharma by 29.5% in the 1st quarter. TimesSquare Capital Management LLC now owns 920,715 shares of the biopharmaceutical company’s stock valued at $42,878,000 after purchasing an additional 209,900 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Acceleron Pharma by 132.1% in the 4th quarter. Bank of New York Mellon Corp now owns 439,644 shares of the biopharmaceutical company’s stock valued at $19,147,000 after purchasing an additional 250,254 shares in the last quarter. Emory University acquired a new stake in shares of Acceleron Pharma in the 4th quarter valued at approximately $1,979,000. Knott David M boosted its stake in shares of Acceleron Pharma by 6.1% in the 4th quarter. Knott David M now owns 17,400 shares of the biopharmaceutical company’s stock valued at $758,000 after purchasing an additional 1,000 shares in the last quarter. Finally, TIAA CREF Investment Management LLC boosted its stake in shares of Acceleron Pharma by 17.5% in the 3rd quarter. TIAA CREF Investment Management LLC now owns 120,784 shares of the biopharmaceutical company’s stock valued at $6,912,000 after purchasing an additional 17,986 shares in the last quarter. Institutional investors own 92.54% of the company’s stock.
XLRN stock opened at $37.63 on Tuesday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 19.26 and a current ratio of 19.26. Acceleron Pharma has a 52 week low of $32.53 and a 52 week high of $59.59. The stock has a market capitalization of $2.01 billion, a P/E ratio of -14.53 and a beta of 1.29.
About Acceleron Pharma
Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.
Featured Story: 52-Week High/Low
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.